Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain

Psychiatry Research

Volumn 225, Issue 3, 2015, Pages 347-354

  Deng, Chao ^a,b,c   Pan, Bo ^a,b   Hu, Chang Hua ^b,d   Han, Mei ^a,b,c   Huang, Xu Feng ^a,b,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d SOUTHWEST UNIVERSITY   (China)

Author keywords

Antipsychotic; Aripiprazole; ErbB4 receptor; Haloperidol; Neuregulin 1; Olanzapine

Indexed keywords

ARIPIPRAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HALOPERIDOL; ISOPROTEIN; NEU DIFFERENTIATION FACTOR; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CINGULATE GYRUS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIPPOCAMPUS; LONG TERM CARE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR UPREGULATION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; DRUG EFFECTS; METABOLISM; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; TIME; UPREGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; FEMALE; HALOPERIDOL; HIPPOCAMPUS; NEUREGULIN-1; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-4; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84922909061     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.12.014     Document Type: Article

References (80)

1. Aravagiri M., Teper Y., Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharmaceutics and Drug Disposition 1999, 20:369-377.
2. Assié M.B., Dominguez H., Consul-Denjean N., Newman-Tancredi A. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn-Schmiedeberg's Archives of Pharmacology 2006, 373:441-450.
3. Barros C.S., Calabrese B., Chamero P., Roberts A.J., Korzus E., Lloyd K., Stowers L., Mayford M., Halpain S., Muller U. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:4507-4512.
4. Benvegnù S., Gasperini L., Legname G. Aged PrP null mice show defective processing of neuregulins in the peripheral nervous system. Molecular and Cellular Neuroscience 2011, 47:28-35.
5. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., Sigmundsson A., Firth D.R., Nielsen B., Stefansdottir R., Novak T.J., Stefansson K., Gurney M.E., Andresson T. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. Journal of Neuroscience 2007, 27:4519-4529.
6. Chana G., Lucero G., Salaria S., Lozach J., Du P., Woelk C., Everall I. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophrenia Research 2009, 113:273-276.
7. Chen M.L., Chen C.H. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2005, 30:268-277.
8. Cheng Y.F., Paalzow L.K. Linear pharmacokinetics of haloperidol in the rat. Biopharmaceutics and Drug Disposition 1992, 13:69-76.
9. Chong V.Z., Thompson M., Beltaifa S., Webster M.J., Law A.J., Weickert C.S. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophrenia Research 2008, 100:270-280.
10. Correll C.U. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. European Psychiatry 2010, 25(Supplement 2):S12-S21.
11. de Leon J., Diaz F.J., Wedlund P., Josiassen R.C., Cooper T.B., Simpson G.M. Haloperidol half-life after chronic dosing. Journal of Clinical Psychopharmacology 2004, 24:656-660.
12. Dejaegere T., Serneels L., Schäfer M.K., Van Biervliet J., Horré K., Depboylu C., Alvarez-Fischer D., Herreman A., Willem M., Haass C., Höglinger G.U., D'Hooge R., De Strooper B. Deficiency of Aph1B/C-γ-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9775-9780.
13. Deng C., Lian J.M., Pai N., Huang X.F. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. Journal of Psychopharmacology 2012, 26:1271-1279.
14. Deng C., Pan B., Engel M., Huang X.F. Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology 2013, 226:201-215.
15. Deng C., Weston-Green K.L., Han M., Huang X.-F. Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:915-920.
16. du Bois T.M., Newell K.A., Huang X.-F. Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life. European Neuropsychopharmacology 2012, 22:356-363.
17. Emsley R. Drugs in developement for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 2009, 18:1103-1118.
18. FDA, 2005. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. FDA Center for Drug Evaluation and Research.
19. Geddes A.E., Huang X.-F., Newell K.A. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:896-904.
20. Ginovart, N., Kapur, S., 2012. Role of dopamine D(2) receptors for antipsychotic activity. Handbook of Experimental Pharmacology, 27-52.
21. Grunder G., Fellows C., Janouschek H., Veselinovic T., Boy C., Brocheler A., Kirschbaum K.M., Hellmann S., Spreckelmeyer K.M., Hiemke C., Rosch F., Schaefer W.M., Vernaleken I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study.[see comment]. American Journal of Psychiatry 2008, 165:988-995.
22. Hahn C.G. A Src link in schizophrenia. Nature Medicine 2011, 17:425-427.
23. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., Gallop R.J., Arnold S.E. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine 2006, 12:824-828.
24. Han M., Huang X.F., Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. International Journal of Neuropsychopharmacology 2009, 12:941-952.
25. Han M., Huang X.F., du Bois T.M., Deng C. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience 2009, 164:1754-1763.
26. Han M., Newell K., Zavitsanou K., Deng C., Huang X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research 2008, 86:457-464.
27. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Society of Biological Psychiatry 2006, 60:132-140.
28. Hashimoto R., Straub R., Weickert C., Hyde T., Kleinman J., Weinberger D. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Molecular Psychiatry 2004, 9:299-307.
29. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry 1996, 153:151-162.
30. Iwakura Y., Nawa H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Frontiers in Cellular Neuroscience 2013, 7:4.
31. Jordan S., Koprivica V., Chen R. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 2002, 441:137-140.
32. Kalinowski A., Plowes N.J.R., Huang Q., Berdejo-Izquierdo C., Russell R.R., Russell K.S. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB Journal 2010, 24:2567-2575.
33. Kampman O., Anttila S., Illi A., Saarela M., Rontu R., Mattila K.M., Leinonen E., Lehtimaki T. Neuregulin genotype and medication response in Finnish patients with schizophrenia. NeuroReport 2004, 15:2517-2520.
34. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003, 27:1081-1090.
35. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Human Molecular Genetics 2007, 16:129-141.
36. Law A.J., Lipska B.K., Weickert C.S., Hyde T.M., Straub R.E., Hashimoto R., Harrison P.J., Kleinman J.E., Weinberger D.R. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. The National Academy of Sciences of the USA 2006, 103:6747-6752.
37. Law A.J., Wang Y., Sei Y., O'Donnell P., Piantadosi P., Papaleo F., Straub R.E., Huang W., Thomas C.J., Vakkalanka R., Besterman A.D., Lipska B.K., Hyde T.M., Harrison P.J., Kleinman J.E., Weinberger D.R. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110 inhibition as a potential therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12165-12170.
38. Lemmens K., Doggen K., De Keulenaer G.W. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. American Journal of Physiology - Heart and Circulatory Physiology 2011, 300:H931-H942.
39. Lewis D.A., Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine 2006, 12:1016-1022.
40. Li J.T., Feng Y., Su Y.A., Wang X.D., Si T.M. Enhanced interaction among ErbB4, PSD-95 and NMDAR by chronic MK-801 treatment is associated with behavioral abnormalities. Pharmacology, Biochemistry, and Behavior 2013, 108:44-53.
41. Lian J., Huang X.-F., Pai N., Deng C. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013, 47:62-68.
42. Lian J., Huang X.-F., Pai N., Deng C. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways. Psychoneuroendocrinology 2014, 48:77-86.
43. Lian J., Huang X.-F., Pai N., Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS ONE 2014, 9:e104160.
44. Lian J., Huang X.-F., Pai N., Deng C. Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015, 56:75-80.
45. Liu C.-M., Hwu H.-G., Fann C.S.J., Lin C.-Y., Liu Y.-L., Ou-Yang W.-C., Lee S.F.C. Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 134B:79-83.
46. Mailman R.B., Murthy V. Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2010, 35:345-346.
47. Mathews M., David J.M. Atypical antipsychotics: new drugs, new challenges. Cleveland Clinic Journal of Medicine 2007, 74:579-606.
48. Matosin N., Frank E., Deng C., Huang X.F., Newell K.A. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophrenia Research 2013, 146:170-176.
49. Mei L., Xiong W.-C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Reviews 2008, 9:437-452.
50. Meltzer H.Y., Massey B.W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 2011, 11:59-67.
51. Natesan S., Svensson K.A., Reckless G.E., Nobrega J.N., Barlow K.B.L., Johansson A.M., Kapur S. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. Journal of Pharmacology and Experimental Therapeutics 2006, 318:810-818.
52. Newell K.A., Deng C., Huang X.-F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research Experimentelle Hirnforschung Expérimentation cérébrale 2006, 172:556-560.
53. Newell K.A., Karl T., Huang X.F. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience 2013, 248:670-680.
54. Newell K.A., Zavitsanou K., Huang X.-F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. NeuroReport 2005, 16:1363-1367.
55. Nicodemus K.K., Law A.J., Radulescu E., Luna A., Kolachana B., Vakkalanka R., Rujescu D., Giegling I., Straub R.E., McGee K., Gold B., Dean M., Muglia P., Callicott J.H., Tan H.-Y., Weinberger D.R. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Archives of General Psychiatry 2010, 67:991-1001.
56. Pan B., Huang X.-F., Deng C. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:924-930.
57. Parlapani E., Schmitt A., Wirths O., Bauer M., Sommer C., Rueb U., Skowronek M.H., Treutlein J., Petroianu G.A., Rietschel M., Falkai P. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. The World Journal of Biological Psychiatry: the Official Journal of the World Federation of Societies of Biological Psychiatry 2010, 11:243-250.
58. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 3rd ed.
59. Pitcher G.M., Kalia L.V., Ng D., Goodfellow N.M., Yee K.T., Lambe E.K., Salter M.W. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nature Medicine 2011, 17:470-478.
60. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008, 22:659-661.
61. Rico B., Marin O. Neuregulin signaling, cortical circuitry development and schizophrenia. Current Opinion in Genetics and Development 2011, 21:262-270.
62. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. NeuroReport 2005, 16:271-275.
63. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5585-5590.
64. Schlagenhauf F., Dinges M., Beck A., Wüstenberg T., Friedel E., Dembler T., Sarkar R., Wrase J., Gallinat J., Juckel G., Heinz A. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophrenia Research 2010, 118:189-200.
65. Shibuya M., Komi E., Wang R., Kato T., Watanabe Y., Sakai M., Ozaki M., Someya T., Nawa H. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. Journal of Neural Transmission 2010, 117:887-895.
66. Shimokawa Y., Akiyama H., Kashiyama E., Koga T., Miyamoto G. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005, 821:8-14.
67. Silberberg G., Darvasi A., Pinkas-Kramarski R., Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. American Journal of Medical Genetics 2006, 141B:142-148.
68. Stefanis N.C., Hatzimanolis A., Smyrnis N., Avramopoulos D., Evdokimidis I., van Os J., Stefanis C.N., Straub R.E., Weinberger D.R. Schizophrenia candidate gene ERBB4: covert routes of vulnerability to psychosis detected at the population level. Schizophrenia Bulletin 2013, 39:349-357.
69. Stefansson H., Sigurdsson E., Steinthorsdottir V. Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 2002, 71:887-892.
70. Steinthorsdottir V., Stefansson H., Ghosh S., Birgisdottir B., Bjornsdottir S., Fasquel A.C., Olafsson O., Stefansson K., Gulcher J.R. Multiple novel transcription initiation sites for NRG1. Gene 2004, 342:97-105.
71. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Molecular Psychiatry 2002, 7:317-321.
72. Tosato S., Bellani M., Bonetto C., Ruggeri M., Perlini C., Lasalvia A., Marinelli V., Rambaldelli G., Cristofalo D., Bertani M., Zanoni M., Lazzarotto L., Cerini R., Pozzi Mucelli R., Tansella M., Dazzan P., Di Forti M., Murray R.M., Collier D.A., Brambilla P. Is neuregulin 1 involved in determining cerebral volumes in schizophrenia? Preliminary results showing a decrease in superior temporal gyrus volume. Neuropsychobiology 2012, 65:119-125.
73. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. American Journal of Psychiatry 2010, 167:1489-1498.
74. Wang X.-D., Su Y.-A., Guo C.-M., Yang Y., Si T.-M. Chronic antipsychotic drug administration alters the expression of neuregulin 1b, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. International Journal of Neuropsychopharmacology 2008, 11:553-556.
75. Weickert C.S., Tiwari Y., Schofield P.R., Mowry B.J., Fullerton J.M. Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Translational Psychiatry 2012, 2:e104.
76. Weston-Green K., Huang X.-F., Deng C. Dosage response of metabolic dysfunction to olanzapine treatment in female Sprague Dawley rats. Behavioural Brain Research 2011, 217:337-346.
77. Woo R.S., Li X.M., Tao Y., Carpenter-Hyland E., Huang Y.Z., Weber J., Neiswender H., Dong X.P., Wu J., Gassmann M., Lai C., Xiong W.C., Gao T.M., Mei L. Neuregulin-1 enhances depolarization-induced GABA release. Neuron 2007, 54:599-610.
78. Zhang H.-X., Zhao J.-P., Lv L.-X., Li W.-Q., Xu L., Ouyang X., Yuan Z.-Q., Huang J.-S. Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neuroscience Letters 2008, 438:1-5.
79. Zhang J.Y., Kowal D.M., Nawoschik S.P., Lou Z., Dunlop J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochemical Pharmacology 2006, 71:521-529.
80. Zhang Q., He M., Deng C., Wang H., Lian J., Huang X.F. Hypothalamic ghrelin signalling mediates olanzapine induced hyperphagia and weight gain in female rats. International Journal of Neuropsychopharmacology 2014.